Diaphragm Disease
Introduction
Diaphragm disease refers to a range of conditions affecting the diaphragm, a crucial muscle separating the chest cavity from the abdomen, essential for respiration. These conditions can compromise the diaphragm's structure or function, leading to varying degrees of respiratory distress and other health complications. While "diaphragm disease" can encompass acquired issues like paralysis from nerve damage or trauma, it often highlights congenital anomalies, particularly congenital diaphragmatic hernia (CDH).
Biological Basis
The diaphragm develops during embryonic growth, a complex process involving multiple tissue types and intricate signaling pathways. Genetic factors are increasingly recognized as playing a significant role in the etiology of congenital diaphragmatic defects. For instance, CDH, where abdominal organs protrude into the chest cavity through a defect in the diaphragm, can be isolated or occur as part of a syndrome. The biological basis involves errors in the fusion of the pleuroperitoneal membranes, muscle ingrowth, or innervation, often influenced by specific genetic variations. Research in consumer genetics aims to identify single nucleotide polymorphisms (SNPs) or other genetic markers that predispose individuals to these developmental errors, shedding light on the molecular pathways involved in diaphragm formation and function.
Clinical Relevance
Clinically, diaphragm disease can manifest from birth or later in life. Congenital forms, like CDH, are typically diagnosed prenatally or shortly after birth, presenting as severe respiratory failure due to lung hypoplasia and pulmonary hypertension. Management often requires immediate surgical intervention and intensive care, with long-term follow-up for associated complications. Acquired conditions, such as diaphragmatic paralysis, can result from injury, neurological disorders, or infections, also leading to breathing difficulties. Understanding the genetic underpinnings can aid in early diagnosis, prognostication, and potentially lead to targeted therapies or improved perioperative management for affected individuals.
Social Importance
The social importance of studying diaphragm disease, especially its congenital forms, is profound. Conditions like CDH carry high morbidity and mortality rates, imposing significant emotional and financial burdens on families and healthcare systems. Identifying genetic risk factors and understanding the biological mechanisms can offer crucial information for genetic counseling, family planning, and prenatal screening. Furthermore, advancements in genetic research contribute to a broader understanding of human development and disease, fostering hope for improved treatments and preventive strategies, ultimately enhancing the quality of life for those affected by diaphragm disease.
Methodological and Statistical Constraints
The research into diaphragm disease faces several methodological and statistical limitations, primarily concerning study power and the scope of genetic variation assessed. The initial genome-wide association study (GWAS) had limited power, approximately 50% to detect an odds ratio (OR) of 2.0, largely due to the challenges associated with recruiting sufficient sample sizes for a relatively rare disease. [1] This constraint means that variants with more modest effect sizes (e.g., OR < 1.2 or 1.3) may not have been detected, leading to an incomplete understanding of the full genetic architecture. [2]
Furthermore, the genotyping arrays used provided less-than-complete coverage of common genetic variations and poor coverage of rare or structural variants, limiting the ability to identify all relevant alleles. [3] While a staged study design aimed to balance the reduction of false positives with the detection of moderate effect sizes [1] a conservative approach to SNP confirmation in replication studies might inadvertently increase the false negative rate. This could result in true associations being missed if not enough promising SNPs are followed up or if the replication cohorts themselves have insufficient power. [4]
Population Specificity and Phenotypic Heterogeneity
The generalizability of findings for diaphragm disease is constrained by the demographic characteristics of the study populations. The cohorts primarily consisted of individuals of Caucasian or European descent. [2] While this homogeneity helps mitigate spurious associations arising from population stratification within the studied groups [1] it also limits the direct applicability of these genetic findings to other ancestral populations. Genetic risk factors and their effect sizes can vary considerably across different ethnic backgrounds, underscoring the need for further investigations in more diverse populations to establish broader relevance.
Additionally, the clinical definition and ascertainment of diaphragm disease can introduce phenotypic heterogeneity. For example, conditions like chronic obstructive pulmonary disease (COPD), which are defined by spirometry, are recognized as heterogeneous. [4] Such variability in how diaphragm disease is diagnosed or classified across different clinical settings can obscure genuine genetic signals or lead to inconsistent associations. A reliance on broad clinical definitions, without detailed sub-phenotyping, might therefore limit the precision with which specific genetic influences on disease manifestations are identified.
Unidentified Genetic Architecture and Environmental Factors
Despite the identification of several associated genetic loci, current studies do not provide an unambiguous identification of the causal genes or a complete understanding of the underlying disease pathogenesis. [2] The observed associations indicate regions of interest, but extensive resequencing, fine-mapping, and functional experiments are still necessary to pinpoint the exact causal polymorphisms and elucidate their biological mechanisms. [2] A significant portion of the genetic susceptibility, often referred to as "missing heritability," remains unexplained, suggesting that many genetic effects, potentially including rarer variants or complex gene-gene interactions, have yet to be discovered. [3]
Furthermore, the etiology of complex conditions like diaphragm disease is often shaped by intricate interactions between genetic predispositions and environmental factors. Although some studies account for known confounders such as age, gender, and smoking status [4] comprehensively assessing all potential environmental exposures and their complex interplay with genetic factors remains a substantial challenge. Unidentified environmental confounders or unrecognized gene-environment interactions could modulate disease risk and progression, potentially masking or altering the apparent effects of genetic variants and contributing to the unexplained variance in disease susceptibility.
Variants
The Wnt signaling pathway, mediated by genes such as WNT5B and WNT3A, plays a fundamental role in orchestrating embryonic development, including cell proliferation, differentiation, and tissue patterning. Variants like rs116521069 in WNT5B and rs992064069 in WNT3A could potentially alter the precise signaling balance required for proper diaphragm formation. Disruptions in Wnt signaling are known to impact mesodermal development and muscle differentiation, processes critical for the diaphragm's complex muscular and tendinous structures. Such genetic variations can contribute to the susceptibility of congenital diaphragmatic defects by influencing the intricate developmental cues that guide lung and diaphragm separation and maturation. [5] This highlights how genetic factors, sometimes identified through genome-wide association studies, can predispose individuals to developmental conditions. [6]
The genetic variant rs184420123 is associated with the LINC01790 locus, which encodes a long intergenic non-coding RNA, and the RNU6-169P pseudogene, related to small nuclear RNAs involved in mRNA splicing. Long non-coding RNAs like LINC01790 are known to play diverse roles in regulating gene expression, influencing processes such as chromatin remodeling, transcription, and post-transcriptional modification. [6] Similarly, RNU6-169P, while a pseudogene, may still have regulatory functions or impact the expression of functional small nuclear RNAs essential for accurate gene splicing. Disruptions in these non-coding RNA pathways due to variants like rs184420123 could impair the precise spatio-temporal gene expression patterns necessary for proper diaphragm development. Such genetic influences underscore the complex interplay of regulatory elements in congenital conditions. [1]
The MIR3171HG gene acts as a host for microRNAs, which are small non-coding RNAs that critically regulate gene expression by binding to messenger RNAs and modulating protein synthesis. The variant rs575815358 within MIR3171HG could potentially affect the transcription, processing, or stability of the microRNAs it encodes, thereby altering their regulatory capacity. MicroRNAs are known to be integral to a wide array of biological processes during embryonic development, including cell proliferation, differentiation, and tissue morphogenesis, all vital for organ formation. [7] Changes in microRNA function due to variants like rs575815358 can lead to imbalances in developmental pathways, potentially contributing to malformations of complex structures such as the diaphragm. The identification of such genetic variants highlights their role in predisposing individuals to developmental disorders. [5]
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs116521069 | WNT5B | diaphragm disease |
| rs992064069 | WNT3A | diaphragm disease |
| rs184420123 | LINC01790 - RNU6-169P | diaphragm disease |
| rs575815358 | MIR3171HG | diaphragm disease |
Clinical Presentation and Phenotypic Characterization
The clinical presentation of diaphragm disease, as with other complex conditions, requires a precise phenotypic definition for effective study and diagnosis. Such definitions are critical for accurate case ascertainment and for distinguishing between different clinical phenotypes. For instance, in other medical contexts, conditions like heart failure are diagnosed based on a comprehensive review of medical records and the presence of specific major and minor criteria. Major criteria can include symptoms such as paroxysmal nocturnal dyspnea, neck vein distention, rales, cardiomegaly on chest radiography, or acute pulmonary edema. Minor criteria, which are only counted if not attributable to another disease, may encompass bilateral ankle edema, nocturnal cough, or shortness of breath on ordinary exertion. [8]
Similarly, the characterization of Kawasaki disease involves criteria such as prolonged fever and at least four of five classical diagnostic signs. Cases may also include children with at least five days of fever and two diagnostic criteria combined with echocardiographic evidence of coronary artery damage, which are considered pathognomonic. The careful establishment of such detailed criteria is essential to maximize the homogeneity of the clinical phenotype within research cohorts, allowing for more robust investigations into underlying disease mechanisms and genetic associations. [1]
Diagnostic Assessment and Measurement Strategies
The assessment of diaphragm disease, mirroring approaches for other conditions, involves a range of diagnostic tools and measurement strategies to confirm diagnosis and evaluate severity. Comprehensive phenotypic data are typically gathered from patient medical files, often complemented by subjective measures such as parental questionnaires. Objective assessment methods, including specific laboratory parameters, are also utilized, although individual biomarkers may sometimes lack sufficient sensitivity or specificity for a definitive diagnosis on their own. [1]
In situations where a single definitive diagnostic test is unavailable, a combination of multiple criteria is often employed. For example, the diagnosis of heart failure necessitates the concurrent presence of either two major criteria or one major and two minor criteria. Expert review by experienced clinicians, such as pediatricians in the case of Kawasaki disease, is also a critical component in validating phenotypic data and ensuring high diagnostic specificity. This multi-faceted approach, integrating objective findings with subjective reports and clinical judgment, is vital for establishing a reliable diagnosis and understanding the full spectrum of the disease. [1]
Variability, Heterogeneity, and Diagnostic Utility
The presentation of diaphragm disease, like other conditions, can exhibit significant inter-individual variation and phenotypic heterogeneity, which are crucial considerations for diagnostic significance. Factors such as age-related changes or sex differences may influence clinical patterns, necessitating careful evaluation during diagnosis and research. For instance, in genetic studies, the importance of demographic factors is implicitly recognized in the analysis of genotype data, where differential rates of missing genotypes are sometimes accounted for between males and females. [9]
To enhance diagnostic value and facilitate the identification of genetic correlations, strategies are often employed to maximize phenotypic homogeneity. This includes the exclusion of atypical presentations or cases with incomplete clinical criteria, as exemplified in studies of Kawasaki disease, where such exclusions aim to create a more uniform patient cohort. The rigorous definition of phenotypes, supported by meticulous review of clinical and laboratory data, serves as a critical step in differential diagnosis, helping to identify red flags, establish prognostic indicators, and guide further clinical and genetic investigations. [1]
Based on the provided context, there is no information directly related to "diaphragm disease." Therefore, a biological background section for this specific trait cannot be generated using the given sources.
Immune Activation and Inflammatory Signaling
The regulation of immune responses and inflammatory cascades is critical for maintaining tissue homeostasis. The macrophage stimulatory protein 1, MST1, plays a significant role in both inflammation and the subsequent tissue remodeling necessary for wound healing. [10] This protein's activity is integral to the broader interplay between innate and adaptive immune responses, which also involves cellular processes like stress fiber formation during innate cellular immune responses. [10] These pathways collectively orchestrate the body's defensive reactions and repair processes.
A key signaling axis in inflammation involves interleukin 6 (IL6), a potent pro-inflammatory cytokine that activates STAT3 (signal transducer and activator of transcription-3). [1] This activation is central to early innate immune reactivity, contributing to acute phase responses characterized by increased levels of acute phase proteins and complement factors. [1] Furthermore, the protein inhibitor of activated STAT (PIAS3) can interact with and inhibit STAT3, providing a critical feedback loop to modulate the inflammatory response. [1] The intricate balance of these signaling events is essential for preventing excessive immune activation and subsequent tissue damage.
Metabolic Regulation and Cellular Homeostasis
Cellular metabolism encompasses a range of pathways vital for energy production, biosynthesis, and waste management. Specific protein processing and energy metabolism pathways are fundamental, with their dysregulation potentially contributing to disease mechanisms. [11] For instance, a novel splice variant of AAK1 functions at multiple stages of the endocytic pathway, which is crucial for nutrient uptake, receptor recycling, and cellular communication. [12] This highlights the importance of precise regulatory mechanisms in maintaining metabolic flux and overall cellular function.
Lysosomal pathways are central to cellular catabolism, responsible for the degradation of various macromolecules. Canonical interactions involving cyclin G associated kinase and adaptor protein 1 regulate the sorting of lysosomal enzymes, ensuring proper delivery and function within the lysosome. [13] A key enzyme in this process, Cathepsin D, is a main lysosomal enzyme involved in protein degradation. [14] Additionally, autophagy, a fundamental catabolic process for cellular recycling, has been implicated in pathogenesis through genes such as ATG16L1. [7] The serine peptidase APEH (APH) also contributes to metabolic regulation by degrading bacterial peptide breakdown products, thereby preventing an excessive immune response in the gut. [10]
Transcriptional and Post-Translational Control
Gene expression is tightly controlled by an array of regulatory mechanisms, including transcription factor activity and post-translational modifications. The enhancer-binding transcription factor ZFHX3 (also known as ATBF1) plays a crucial role in gene regulation and is known to be polymorphic. [1] This factor interacts with PIAS3, which in turn inhibits the activity of the transcription factor STAT3, demonstrating a direct regulatory link between a transcription factor and a key signaling pathway. [1] Such interactions allow for precise control over gene expression in response to cellular cues.
Post-translational modifications of proteins are vital for modulating their activity, stability, and interactions. CSMD1 (CUB and Sushi multiple domains 1) is functionally related to CaM Kinase II (calcium/calmodulin-dependent protein kinase II) through its association with HDAC4 (histone deacetylase 4). [1] This connection illustrates how protein modifications, such as histone deacetylation, can impact signaling pathways and gene expression, influencing cellular responses. [1] Dysregulation in the expression of immunoregulatory and cytokine genes further underscores the importance of these control mechanisms in maintaining physiological balance. [15]
Tissue Integrity, Remodeling, and Crosstalk
The maintenance of tissue integrity and the capacity for remodeling are complex processes involving the coordinated action of multiple pathways and cell types. Proteins like the scaffolding protein encoded by the BSN gene contribute to the structural organization of cells, particularly in axons. [10] The process of tissue repair and remodeling, often initiated following inflammation, involves proteins such as MST1. [10] These mechanisms are crucial for restoring tissue function after injury or disease.
At a systems level, various biochemical pathways converge on pathophysiological mechanisms central to epithelial defense and the dynamic interplay between innate and adaptive immune responses. [10] The integrity of muscle structure is exemplified by MYH7 (myosin, heavy chain 7), a protein in which mutations are known to cause inherited cardiomyopathy, highlighting its essential role in muscle function. [1] Furthermore, endothelial cells play a critical role in tissue health, and their function can be compromised, as seen in impaired endothelial function and decreased nitric oxide production, which contribute to pathophysiological signaling and vascular damage. [16] These interconnected pathways demonstrate the hierarchical regulation and emergent properties that arise from complex biological networks.
Genetic Insights into Risk and Diagnosis
Genetic studies, particularly genome-wide association studies (GWAS), play a crucial role in enhancing the understanding of conditions like diaphragm disease by pinpointing specific susceptibility loci. Identifying genetic variants, such as single nucleotide polymorphisms (SNPs), that are significantly associated with the disease can inform diagnostic utility and risk assessment. For instance, the robust identification of genetic risk factors for other complex conditions, often using stringent statistical criteria and replication in independent cohorts, demonstrates the potential for similar insights in diaphragm disease. [4] This allows for the identification of individuals who may be at a higher genetic risk, even before clinical symptoms manifest, paving the way for targeted screening and early intervention strategies.
Such genetic insights are foundational for personalized medicine approaches, enabling clinicians to tailor preventative measures or surveillance protocols for high-risk individuals. The development of predictive models based on identified genetic markers can contribute to more accurate risk stratification, moving beyond traditional clinical factors alone. While no single variant has yet provided clinically useful prediction of disease on its own for most common conditions, the cumulative effect of multiple genetic loci holds promise for improved risk assessment. [3] For diaphragm disease, this could translate into personalized recommendations for lifestyle modifications or specific medical monitoring based on an individual's genetic predisposition.
Prognostic Indicators and Disease Progression
Genetic variants associated with diaphragm disease may serve as valuable prognostic indicators, offering insights into anticipated disease trajectory and potential outcomes. Studies on other complex diseases have shown that genetic factors can contribute significantly to an individual's risk and the natural history of their condition. [4] For example, genetic variants influencing the age of disease onset have been identified for other conditions, suggesting that similar markers could predict an earlier or later presentation of diaphragm disease. [17] This prognostic information can help manage patient expectations and facilitate proactive planning for long-term care.
Beyond onset, genetic markers could also predict the rate of disease progression or the likelihood of specific complications related to diaphragm disease. Understanding these genetic influences allows for improved patient stratification, guiding clinicians in the intensity of monitoring required and potentially indicating which patients might benefit most from early or aggressive therapeutic interventions. The consistent replication of genetic associations across populations with varying disease severities in other contexts supports the potential for such genetic markers to be robust indicators of disease course. [4]
Therapeutic Implications and Comorbidity Understanding
The identification of genetic loci involved in diaphragm disease could significantly impact treatment selection and the development of targeted therapies. While specific gene-drug interactions for diaphragm disease are not detailed in research, the broader field of pharmacogenomics, driven by genetic discoveries, aims to optimize treatment response and minimize adverse effects based on an individual's genetic makeup. For instance, understanding the molecular pathways influenced by disease-associated genes, such as SP-B binding protein's role in lung surfactant expression in chronic obstructive pulmonary disease, could reveal novel therapeutic targets or predict responsiveness to existing treatments for diaphragm disease. [4] This personalized approach could lead to more effective disease management and better patient outcomes.
Furthermore, genetic studies can shed light on potential comorbidities and overlapping phenotypes, which is crucial for a holistic understanding of diaphragm disease. The observation of shared genetic susceptibility between seemingly distinct conditions, such as the potential overlap in genes for chronic obstructive pulmonary disease and asthma, highlights the importance of investigating related conditions. [4] Identifying genetic links between diaphragm disease and other disorders could uncover shared biological mechanisms, leading to improved recognition of syndromic presentations or complications, and informing comprehensive monitoring strategies. This expanded understanding supports integrated care pathways, addressing the full spectrum of a patient's health needs.
Frequently Asked Questions About Diaphragm Disease
These questions address the most important and specific aspects of diaphragm disease based on current genetic research.
1. If I had a congenital diaphragm problem, will my children definitely get it too?
Not necessarily, but your children might have an increased risk. While genetic factors play a significant role in congenital diaphragm conditions, it's a complex interaction. Many specific genetic variations contributing to these conditions are still being discovered, and it's not always a straightforward inheritance pattern. Genetic counseling can help you understand your family's specific risks.
2. Can doctors tell me if my baby might have a diaphragm problem before birth?
Yes, congenital diaphragm conditions like CDH are often diagnosed prenatally, typically through ultrasound. This early diagnosis is very important for planning the specialized care your baby might need immediately after birth. Understanding the genetic influences helps doctors provide better guidance on potential outcomes.
3. My sibling had a diaphragm issue, but I didn't. Why the difference?
Even within the same family, the manifestation of genetic predispositions can vary. While you might share some genetic factors, other specific genetic variations or even unidentified environmental influences could have played a role in your sibling's condition that didn't affect you. The full genetic picture is often complex.
4. Why is it so hard for doctors to find the exact cause of these conditions?
It's challenging because diaphragm disease is complex, and the specific genetic architecture is still largely being uncovered. Many genetic effects, including rarer variations or complex interactions between different genetic factors, have yet to be identified. Plus, environmental factors are also thought to play a role, making the overall cause even more intricate.
5. Does my ethnic background affect my risk for these breathing problems?
Yes, genetic risk factors and their effects can vary considerably across different ethnic backgrounds. Most research to date has primarily focused on individuals of European descent, so more studies in diverse populations are needed to fully understand how your specific ancestry might influence your risk.
6. Can what I do during pregnancy affect my baby's diaphragm development?
While genetic predispositions are a major factor, the development of complex conditions like diaphragm disease is often shaped by intricate interactions between genetic makeup and environmental factors. Some environmental exposures could play a role, but these are still largely unidentified and complex to assess fully.
7. Why do some babies have severe diaphragm issues from birth and others have mild ones?
The severity can vary greatly due to the specific nature of the defect and how it impacts lung development. Different genetic variations involved can lead to a range of outcomes, from a small defect to a severe congenital diaphragmatic hernia causing significant lung underdevelopment and breathing difficulties.
8. Is there a genetic test I can take to know my personal risk before having kids?
While research is actively identifying genetic markers, current studies haven't fully pinpointed all the causal genes or explained the complete genetic susceptibility. Therefore, a single comprehensive genetic test to predict all personal risk factors for future children isn't fully available yet, but genetic counseling can evaluate known family risks.
9. Why is it so hard to prevent these diaphragm conditions from happening?
It's challenging because the full genetic and environmental causes are not yet completely understood. While we know genetic factors play a significant role, much of the "missing heritability" remains unexplained. This means many genetic effects and their complex interactions with environmental factors are still being discovered, making prevention strategies difficult to pinpoint.
10. Are doctors learning new ways to treat these conditions based on genetics?
Yes, understanding the genetic underpinnings is crucial for advancing treatments. This knowledge can aid in early diagnosis, better prognostication, and potentially lead to more targeted therapies or improved perioperative management for affected individuals, offering hope for better outcomes.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
[1] Burgner D et al. "A genome-wide association study identifies novel and functionally related susceptibility Loci for Kawasaki disease." PLoS Genet. 2009.
[2] Barrett, Jeffrey C., et al. "Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease." Nature Genetics, vol. 40, no. 8, 2008, pp. 955-962.
[3] Wellcome Trust Case Control Consortium. "Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls." Nature, vol. 447, no. 7145, 2007, pp. 661-678.
[4] Pillai, S. G., et al. "A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci." PLoS Genetics, vol. 5, no. 3, 2009, e1000421.
[5] Garcia-Barcelo MM et al. "Genome-wide association study identifies NRG1 as a susceptibility locus for Hirschsprung's disease." Proc Natl Acad Sci U S A. 2009.
[6] Pankratz N et al. "Genomewide association study for susceptibility genes contributing to familial Parkinson disease." Hum Genet. 2008.
[7] Rioux JD et al. "Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis." Nat Genet. 2007.
[8] Larson, MG. "Framingham Heart Study 100K project: genome-wide associations for cardiovascular disease outcomes." BMC Med Genet, 2007.
[9] Latourelle, JC. "Genomewide association study for onset age in Parkinson disease." BMC Med Genet, 2009.
[10] Raelson, JV. "Genome-wide association study for Crohn's disease in the Quebec Founder Population identifies multiple validated disease loci." Proc Natl Acad Sci U S A, 2007.
[11] Zhang, Y. et al. "Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms." Am J Med Genet B Neuropsychiatr Genet, 2005.
[12] Henderson, DM., and SD. Conner. "A novel AAK1 splice variant functions at multiple steps of the endocytic pathway." Mol Biol Cell, 2007.
[13] Kametaka, S. et al. "Canonical interaction of cyclin G associated kinase with adaptor protein 1 regulates lysosomal enzyme sorting." Mol Biol Cell, 2007.
[14] Sevlever, D. et al. "Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species." Biochemistry, 2008.
[15] Satwani, P. et al. "Dysregulation of expression of immunoregulatory and cytokine genes and its association with the immaturity in neonatal phagocytic and cellular immunity." Biol Neonate, 2005.
[16] Deng, YB. et al. "Impaired endothelial function in the brachial artery after Kawasaki disease and the effects of intravenous administration of vitamin C." Pediatr Infect Dis J, 2003.
[17] Carrasquillo, Michael M., et al. "Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease." Nature Genetics, vol. 41, no. 2, 2009, pp. 192-198.